Arcus Biosciences (RCUS) Expected to Announce Quarterly Earnings on Tuesday

Arcus Biosciences (NYSE:RCUS - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Arcus Biosciences to post earnings of ($1.02) per share and revenue of $38.61 million for the quarter.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $36.00 million during the quarter, compared to analysts' expectations of $29.38 million. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Arcus Biosciences Stock Performance

Shares of RCUS traded up $0.11 during mid-day trading on Friday, hitting $8.73. 21,303 shares of the company's stock were exchanged, compared to its average volume of 807,425. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The business's 50 day moving average is $8.60 and its two-hundred day moving average is $12.81. The firm has a market capitalization of $918.17 million, a P/E ratio of -2.75 and a beta of 1.54.

Insiders Place Their Bets

In other news, Director Yasunori Kaneko acquired 20,000 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now directly owns 28,400 shares in the company, valued at $285,704. This trade represents a 238.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Terry J. Rosen purchased 19,800 shares of the company's stock in a transaction on Thursday, February 27th. The stock was purchased at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the purchase, the chief executive officer now directly owns 2,554,160 shares of the company's stock, valued at $26,001,348.80. This trade represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

RCUS has been the topic of a number of recent analyst reports. Bank of America dropped their price objective on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. Barclays lowered their target price on Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating on the stock in a report on Wednesday, April 23rd. HC Wainwright raised shares of Arcus Biosciences from a "neutral" rating to a "buy" rating and raised their price target for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley cut their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Arcus Biosciences has an average rating of "Buy" and a consensus price target of $28.38.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.